Market Size (2018)
$9.73B
Vertical: HealthcareBase Year: 2018
Market Size (2018)
$9.73B
Projected (2025)
$16.29B
CAGR (2016–2025)
6.9%
Key Players
10+
Metabolomics can be defined as the study and analysis of the biochemical processes involving intermediates and byproducts of metabolic activities. These products are known as metabolomes, which reflect the cluster of all metabolites involved in various reactions in an organism, which include signaling molecules, secondary metabolites, metabolic intermediates, and hormones.
Metabolomics involves the use of numerous analytical techniques for the determination of metabolites such as chromatography, spectroscopy, and multivariate analysis. Metabolites are related to the phenotype of an organism and can be used for an extensive range of applications such as phenotyping of genetically modified plants, substantial equivalence testing, biotic-abiotic stress reaction analysis, and for the identification of gene function. Additionally, it facilitates researchers and scientists to analyze physiological effects and witness the adverse reaction of drugs on an organism.
The Metabolomics Services Market market is projected to grow at a CAGR of 6.9% from 2016 to 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMetabolomics Services Market
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
The scope of the global metabolomics services market study includes the market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on products and services, application, and region.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global metabolomics services market is characterized by the presence of global, regional, and local vendors. The market is highly competitive with all players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for the vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.
The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional, and foreign players with small market shares also have a presence. The international players may strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share. Vendors with better technical and financial resources could develop innovative products. Therefore, vendors must develop new technologies and stay abreast of emerging technologies that could affect the continuing competitiveness of their treatment lines in the market.
Bargaining Power of Suppliers
Currently, the market consists of a number of players manufacturing novel metabolomics services used for drug development and diagnosis purpose. However, few existing key companies capture significant share in the market and have the capability of fluctuating the costs of the product and services related to the market. Another factor affecting the bargaining power of suppliers is the switching cost for buyers. Furthermore, many companies are focusing on the development of new metabolomic services, which increases competition in the market. Therefore, the overall bargaining power of suppliers in the global metabolomics services market is moderate.
Bargaining Power of Buyers
The bargaining power of buyers is medium to high in the global metabolomics services market. The pharmaceutical, biotech, hospitals, and diagnostic centers are the major buyers for the market through a specific distribution channel. The presence of buyers in the market is rising due to the increasing prevalence of cancer and cardiac diseases. In addition, the pricing factor also plays an important role in the bargaining power of the buyer in the market. The market is characterized by moderate availabilities of substitute products, which reduces the buying power to an extent.
Threat of New Entrants
The threat of new entrants is medium in the global metabolomics services market due to the development of the potential market. Any company trying to enter the market has to get the product approved and certified by various regulatory authorities in different countries. The huge cost of R&D and product development may restrain the entry of new players into the market.
Threat of Substitutes
The threat of substitutes in the global metabolomics services market is medium to low. Any threat from a close substitute product is measured to have a high impact on the market. The threat from the substitutes arises when the buyers or the customers in the market can accomplish the end-result using other similar product. Although there is a moderate number of substitutes available in the market.
Intensity of Rivalry
The degree of competition in the global metabolomics services market is medium to high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Companies involved in the metabolomics services market are trying to develop cost-effective products to make product differentiation more affordable. To overcome the competition, players are engaged in developing a process to lower their manufacturing cost. Moreover, the players are also developing advanced techniques for differentiating their product from their rivals.
Market estimates by geography (2025)
InsightAmericas leads with $6.04B by 2025, while Asia Pacific is projected to grow fastest at a 7.2% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Asia Pacific | $2.44B | $3.33B | $4.55B | 7.2% | 28% |
| Americas | $3.28B | $4.44B | $6.04B | 7.0% | 37% |
| Europe | $2.93B | $3.96B | $5.37B | 6.9% | 33% |
| Middle East and Africa | $259.30M | $292.60M | $334.20M | 2.9% | 2% |
| Total | $8.91B | $12.02B | $16.29B | 6.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$16.29B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Chromatography | $7.86B | 6.9% | 48% |
| Metabolomics Bioinformatics Services | $4.38B | 7.1% | 27% |
| Mass Spectrometry | $3.51B | 7.0% | 22% |
| Others | $541.50M | 4.6% | 3% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Metabolomics Services Market covering market dynamics, competitive landscape, and strategic outlook.
The Metabolomics Services Market market is projected to reach $16.29B by 2025, growing at 6.9% CAGR. The Chromatography segment holds the largest share.
The key factors driving the growth of the metabolomics services market are growing prevalence of diseases such as cancer, neurological disorders, and cardiac diseases across the globe. Also, other factors such as technological advancements in instrumentation and increasing application of metabolomics in the life science and biotechnological industry are increasing the demand for the metabolomics services market. However, factors such as high cost of instruments and government policies and regulations may hamper the growth of metabolomics services market.
Metabolite analysis is effectively used in the early diagnosis of various disorders such as cancer, neurological disorder, cardiac diseases, and others. Amongst the different clinical indications, cancer is the largest contributor to the metabolomics services market. This is largely due to the global rise in incidences of cancer and growing oncological research activities. According to the World Health Organization (WHO), cancer has been the second leading cause of deaths globally and accounted for 8.8 million deaths in 2015. Also, according to the National Cancer Institute in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the US. Other clinical indications for metabolomics are cardiovascular disorders, neurological disorders, inborn errors of metabolism and others. Such an increase in the use of metabolomics in the detection of chronic diseases in the healthcare industry is boosting the growth of the metabolomics services market.
The metabolomics services market has witnessed various technological advancements to meet the needs of biotechnology and biopharmaceutical companies; food and beverage, chemical, semiconductor industries; and environmental testing. These advancements have led to the development of miniaturized, automated, and computerized devices. These technological advancements have increased the convenience and ease of use of analytical devices. Technological advancements and automation are expected to increase further in the future, leading to the growth of the market.
Increasing application of metabolomics in the life science and biotechnological industry due to its wide application in biochemical screening of genetic disorders, therapeutic drug monitoring and toxicology, vitamins and related metabolites, have led to the overall market growth of the metabolomics services market. Easy and automated process makes it easier to separate two molecules and perform various functions and tests in less time. Major companies such as Thermofisher, Agilent Technologies, and Bruker Corporation, are increasing collaborations with research communities and educational institutes to fund them for more research with combination, separation, and detection technique licenses. For instance, Cenix Bioscience GmbH inked an agreement with Metanomics Health GmbH for the development of metabolomic biomarkers in August 2014. Moreover, in July 2017, Thermo Fisher Scientific joined forces with SRI international for the development of small molecule research. The increasing research and development in the field of metabolomics are driving the growth of the market.
Developing countries provide great opportunities and potential market for metabolomics. Developing infrastructure and healthcare expenditure in these countries provide large opportunities to the players in the metabolomics services market. Also, the growing academic, biotechnology and pharmaceutical industries in these countries is the other factor leading to future growth opportunities in the market. In the present scenario, developing countries are giving importance to developing healthcare facilities and have included an enormous funding plan for the healthcare industry which will help in bringing technologically advanced machines, improved healthcare research centers, and high level of education.
The hospitals, clinics, and many other healthcare facilities are highly dependent on metabolite analysis, and it requires additional applications/software to be installed in the systems, which increases the expenses. The systems also require the installation of other hardware devices that may raise the cost of the system. The high cost of metabolomics services may act as a barrier in both developed and developing countries and creates a lot of problems for new manufacturers to enter into this market.
Furthermore, maintenance charges also contribute to the high cost. In 2015, researchers at Cornell University stated in an article published in Chemical & Engineering News that they paid 25% more to Bruker Corp. to upgrade a nuclear magnetic resonance spectrometer. Thus, the high cost of metabolomics is likely to restrain the growth of the global metabolomics services market during the forecast period.
Changing government policies and regulations for medical instruments manufacturing and shipment or exports are some other factors limiting market growth. Government policies for medical instruments and products differ with country and also increases the burden on the seller or manufacturer regarding tax and other duties that need to be paid, hence decreasing the margin for both the manufacturer and the supplier.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 105 companies operating in the Metabolomics Services Market market, including revenue, employee count, and market positioning where available.
Showing 105 of 105 companies
Bruker
Company Headquarters: Massachusetts, US Founded: 1960 Workforce: ~6500 Company Working: Bruker is specialized as the developer, manufacturer, and distributor of scientific instruments, analytical, and diagnostic solutions products. Bruker operates through two segments, namely Bruker Scientific Instruments and Bruker Energy & Supercon Technologies. It has technical and manufacturing centers present across Europe and North America. The company is making significant investments in R&D, to introduce innovative manufacturing processes.
Human Metabolome Technologies America Inc
Company Headquarters: Japan Founded: 2003 Workforce: ~50 Company Working: Human Metabolome Technologies America Inc. is a biotechnology company in capillary electrophoresis-mass spectrometry (CE-MS)-based metabolome analysis. The company operates through two segments— metabolome analysis and biomarker. The metabolome analysis segment provides analysis services used to analyze and measure metabolomics samples. The biomarker segment involved in the exploration of biomarkers, and the R&D of in vitro diagnostic drugs and equipment. The pharmaceutical, biotech, and food industry are the key customers of the company and use these products for drug discovery and diagnosis purpose. Geographically the company is located in the Americas, Europe, and Japan.
CREATIVE PROTEOMICS
Company Headquarters: New York, US Founded: 2004 Workforce: ~200 Company Working: Creative Proteomics, an integrated biotech contract research organization (CRO), is involved in providing a full range of drug development services which includes metabolomics, glycomics, proteomics, and bioinformatics analysis services used for research in the biotechnology, pharmaceutical, nutrition, and agriculture industries, and in some cases used by academic and government organizations. The company specializes in protein identification, protein quantification, metabolomics service, protein gel, and imaging analysis, protein post-translational modification analysis, and lipidomics service.
Biocrates Life Sciences AG
Company Headquarters: Austria Founded: 2003 Workforce: ~50 Company Working: Biocrates Life Sciences AG (Biocrates) is a global solution provider for metabolomics services. In addition to metabolomics services, the company is engaged in developing clinical biomarker assays and quality control assays to advance clinical study outcomes. The product offered by the company such as Biocrates biomarkers focuses on diagnostic of diabetes, early diagnosis of pancreatic cancer (PDAC), congestive heart failure (CHF), kidney disease, sepsis, stroke, and various types of cancer such as ovarian and breast cancer.
TMIC
Company Headquarters: Alberta, Canada Founded: 2011 Workforce: ~51-200 Company Working: TMIC (The Metabolomics Innovation Centre) is a nationally-funded core facility. It has an exceptional blend of infrastructure and employees to accomplish a wide range of cutting-edge metabolomic studies for clinical trials research, bioproducts studies, nutrient profiling biomedical studies, and environmental testing. It offers a diverse set of technologies for targeted, quantitative, and untargeted metabolomics using nuclear magnetic resonance (NMR), gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), and metabolite imaging. TMIC is widely spread, fee-for-service, university-based core facility providing quantitative metabolomics services for Canada’s public and private research sectors.
Shimadzu Corporation
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence